Clinical Trial ResultsModerna's mRNA-4157 in combination with Keytruda reduced the risk of recurrence or death in melanoma patients by 49%.
New Product ApprovalModerna recently had its second-ever product approved, as the FDA approved mRESVIA, an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Vaccine SafetyNo GBS cases deemed related to mRESVIA have occurred to date, making mRESVIA one of the safest amongst peers to date.